dc.contributor.author
Kühnen, Peter
dc.contributor.author
Wiegand, Susanna
dc.contributor.author
Biebermann, Heike
dc.date.accessioned
2025-10-14T10:02:29Z
dc.date.available
2025-10-14T10:02:29Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/49816
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-49541
dc.description.abstract
The leptin-melanocortin pathway is playing a pivotal role for central body weight regulation. The melanocortin 4 receptor (MC4R) is essential to induce satiety after activation by the endogenous ligands α-/β-melanocyte-stimulating hormone. The relevance of biased signaling is exemplified by an MC4R agonist, which has been approved for the treatment of rare forms of monogenic obesity. Here biased signaling is discussed as new option to develop drugs with an improved safety profile.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
leptin-melanocortin
en
dc.subject
body weight regulation
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Biased signaling: Option für die Entwicklung von Adipositas-Medikamenten?
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1007/s12268-023-1895-x
dcterms.bibliographicCitation.journaltitle
BIOspektrum
dcterms.bibliographicCitation.number
1
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.volume
29
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.isPartOf.issn
0947-0867
dcterms.isPartOf.eissn
1868-6249
